AN OBSERVATIONAL STUDY OF PATIENTS WITH NEWLY DIAGNOSED UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) IN CHINA

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-14004843

Enrollment

Unknown

Registered

2014-06-24

Start date

2014-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NEWLY DIAGNOSED UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC)

Interventions

1:Anti-NSCLC drugs

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Phase A: 1. will consist of approximately 300 patients (50 patients per site) with unresectable Stage IIIB or IV NSCLC who were newly diagnosed at the site or referred to the site for treatment after a new diagnosis at another facility between January and July 2013, provided that all cancer-specific historical data points are available in the medical record. Phase B: 1. will consist of approximately 2100 patients (350 patients per site) with newly diagnosed unresectable Stage IIIB or IV NSCLC; 2. Willing to sign informed consent ?Histologically/cytologically confirmed, unresectable Stage IIIB or IV NSCLC; 3. Radiographic evidence of disease.

Exclusion criteria

Exclusion criteria: Phase A: Patients who have participated in anti-cancer, regimen-specified clinical studies prior to enrollment. Phase B: 1. Prior treatment for unresectable Stage IIIB or IV NSCLC; 2. Participated in any anti-cancer, regimen-specified clinical studies for first NSCLC treatment.

Design outcomes

Primary

Measure	Time frame
progression-free survival;overall survival;	—

Countries

China

Contacts

Public ContactLv ZHOU

F. Hoffmann-La Roche Ltd

zl_roche@163.com+86 021-5080 1142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026